Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Sandoz Japan on Hunt for Biosimilar In-Licensing, Sales Tie-Ups after Avastin Deal
May 26, 2022
- Japan Pharma Market Up 3.3% in FY2021, Opdivo Rises to No.1: IQVIA
May 26, 2022
- Vabysmo, Ondexxya, Ozempic 2 mg Pen Now Available in Japan
May 26, 2022
- Novavax Vaccine Officially Added to Japan’s Free COVID-19 Inoculation Program
May 26, 2022
- BMS CEO Sees Faster Drug Development as Industry Imperative after COVID Vaccine Feat
May 25, 2022
- US Business Made or Broke FY2021 Earnings of Big 3 Generic Makers; Nichi-Iko, Sawai Suffer Losses
May 24, 2022
- Healios Continues to Seek MultiStem Approval despite Trial Miss: CEO
May 24, 2022
- Tohoku Univ., Drug Makers, MICIN to Jointly Collect Lifestyle Data with Wearable
May 24, 2022
- OrphanPacific Grabs Japan Rights to Immedica Drug for Urea Cycle Disorder
May 24, 2022
- Shionogi President Teshirogi to Also Become Chairman from July
May 24, 2022
- First Wipe Drug for Axillary Hyperhidrosis Now Available in Japan
May 24, 2022
- Healios’ Sakigake Cell Therapy Misses Goal in Ischemic Stroke
May 23, 2022
- US Court Dismisses Astellas Claim over Lexiscan Patent
May 23, 2022
- Movicol High-Dose Version Launched for Constipation: EA Pharma
May 23, 2022
- Fostering Biopharma Startups Is Vital to New Drug Development in Japan: IQVIA
May 20, 2022
- Opdivo Expands Indication in Taiwan for RCC in Combo with Cabozantinib
May 20, 2022
- A Few More Years before Human Trials Can Start for Potential Diabetes Cure, Novo CSO Says
May 20, 2022
- AbbVie’s Japan Sales Sag 13% in 2021 as Off-Year Price Cuts, Synagis Return Weigh
May 19, 2022
- Sosei, Kallyope Partner in R&D of GPCR Targets for GI Drug Discovery
May 18, 2022
- Argenx CEO Sees Big Potential for Vyvgart with 100-Plus Diseases Driven by IgGs; Analysts Peg Peak Sales at US$5-10 Billion
May 18, 2022
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…